G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway.

The Hippo pathway is crucial in organ size control, whereas its dysregulation contributes to organ degeneration or tumorigenesis. The kinase cascade of MST1/2 and LATS1/2 and the coupling transcription co-activators YAP/TAZ represent the core components of the Hippo pathway. Extensive studies have identified a number of upstream regulators of the Hippo pathway, including contact inhibition, mechanic stress, extracellular matrix stiffness, cytoskeletal rearrangement, and some molecules of cell polarity and cell junction. However, how the diffuse extracellular signals regulate the Hippo pathway puzzles the researchers for a long time. Unexpectedly, recent elegant studies demonstrated that stimulation of some G protein-coupled receptors (GPCRs), such as lysophosphatidic acid receptor, sphingosine-1-phosphate receptor, and the protease activated receptor PAR1, causes potent YAP/TAZ dephosphorylation and activation by promoting actin cytoskeleton assemble. In this review, we briefly describe the components of the Hippo pathway and focus on the recent progress with respect to the regulation of the Hippo pathway by GPCRs and G proteins in cancer cells. In addition, we also discuss the potential therapeutic roles targeting the Hippo pathway in human cancers.

[1]  G. Bonamy,et al.  Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. , 2012, Chemistry & biology.

[2]  K. Guan,et al.  Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. , 2011, Genes & development.

[3]  O. Kirak,et al.  Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation , 2011, Cell.

[4]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[5]  R. Müller,et al.  NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway , 2011, The Journal of cell biology.

[6]  Zhengyu Zha,et al.  The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCFβ-TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition* , 2012, The Journal of Biological Chemistry.

[7]  K. Guan,et al.  A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.

[8]  K. Guan,et al.  The Hippo pathway: regulators and regulations. , 2013, Genes & development.

[9]  Gary D Bader,et al.  Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. , 2010, The Biochemical journal.

[10]  G. Longmore,et al.  Ajuba LIM Proteins Are Negative Regulators of the Hippo Signaling Pathway , 2010, Current Biology.

[11]  J. Stockman Mutations in GNA11 in Uveal Melanoma , 2012 .

[12]  Zhengyu Zha,et al.  The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.

[13]  Q. Zeng,et al.  A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.

[14]  C. Wells,et al.  LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap , 2013, Oncogene.

[15]  Kun-Liang Guan,et al.  Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. , 2013, Genes & development.

[16]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[17]  S. Seshagiri,et al.  The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer , 2013, Nature Reviews Cancer.

[18]  Zhengyu Zha,et al.  TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.

[19]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[20]  H. Cai,et al.  The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells , 2013, Cell Communication and Signaling.

[21]  Eun Jin Seo,et al.  TAZ Mediates Lysophosphatidic Acid-Induced Migration and Proliferation of Epithelial Ovarian Cancer Cells , 2013, Cellular Physiology and Biochemistry.

[22]  Yiqiang Zhao,et al.  Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-actin Binding, Cell Migration, and Angiogenesis* , 2013, The Journal of Biological Chemistry.

[23]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[24]  Bin Zhao,et al.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.

[25]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[26]  A. Stemmer-Rachamimov,et al.  A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. , 2011, Cancer cell.

[27]  G. Barsh,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .

[28]  V. Sah,et al.  The role of Rho in G protein-coupled receptor signal transduction. , 2000, Annual review of pharmacology and toxicology.

[29]  Sirio Dupont Role of YAP/TAZ in mechanotransduction , 2011 .

[30]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[31]  M. Giovannini,et al.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. , 2010, Developmental cell.

[32]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[33]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[34]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[35]  Zhengyu Zha,et al.  TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.

[36]  Junjie Chen,et al.  PTPN14 is required for the density-dependent control of YAP1. , 2012, Genes & development.

[37]  C. Wells,et al.  Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases , 2013, Proceedings of the National Academy of Sciences.

[38]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[39]  K. Guan,et al.  Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). , 2012, Genes & development.

[40]  M. Goppelt‐Struebe,et al.  Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.

[41]  M. Sudol,et al.  Structures of YAP protein domains reveal promising targets for development of new cancer drugs. , 2012, Seminars in cell & developmental biology.

[42]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[43]  Y. Hata,et al.  A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. , 2011, Journal of biochemistry.

[44]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[45]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[46]  Stefan Offermanns,et al.  Mammalian G proteins and their cell type specific functions. , 2005, Physiological reviews.

[47]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[48]  Junjie Chen,et al.  Angiomotin-like Proteins Associate with and Negatively Regulate YAP1* , 2010, The Journal of Biological Chemistry.

[49]  M. Ji,et al.  KIBRA Regulates Hippo Signaling Activity via Interactions with Large Tumor Suppressor Kinases* , 2011, The Journal of Biological Chemistry.

[50]  Y. Cho‐Chung Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. , 1990, Cancer research.

[51]  Jindan Yu,et al.  Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.

[52]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[53]  Kevin J. Cheung,et al.  Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.

[54]  D. Faratian,et al.  KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals , 2013, Oncogene.

[55]  G. Merlino,et al.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. , 2014, Cancer cell.

[56]  Kang Zhang,et al.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.

[57]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[58]  M. Hollenberg,et al.  Thrombin‐mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase‐activated receptors 1 and 4 , 2007, Journal of cellular physiology.

[59]  Li Li,et al.  The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.

[60]  H. Saya,et al.  cAMP/PKA signalling reinforces the LATS–YAP pathway to fully suppress YAP in response to actin cytoskeletal changes , 2013, The EMBO journal.

[61]  K. Harvey,et al.  Upstream Regulation of the Hippo Size Control Pathway , 2010, Current Biology.

[62]  K. Song,et al.  Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. , 2012, Anticancer research.

[63]  C. Der,et al.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.